Dr. Lal PathLabs: Final Dividend of ₹4/Share Approved

Dr. Lal PathLabs Ltd's board approved the audited financial results for the quarter and financial year ended March 31, 2026, and recommended a final dividend of ₹4 per equity share (40% on a face value of ₹10 each), subject to shareholder approval at the AGM. The record date for the dividend is June 26, 2026. The company will acquire 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary. Additionally, Dr. Lal PathLabs will incorporate a wholly-owned subsidiary in Dubai, UAE. The board also approved the re-appointment of Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as a Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal Auditors and Cost Auditors, respectively. 82,750 Equity Shares were allotted under Employee Stock Option Plan 2022.